Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.
The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.
Vanda Pharmaceuticals SVP, CFO & Treasurer Kevin Patrick Moran reported an open-market sale of 42,442 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The filing explains these shares were sold to satisfy tax obligations arising from the settlement of vested RSUs under withholding provisions in the RSU agreements. After the sale, Moran directly held 411,380 common shares and indirectly held 635 additional shares through his wife. The sale occurred in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals Inc. senior vice president and chief marketing officer Joakim Wijkstrom executed an open‑market sale of 30,800 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under the company’s RSU agreements, rather than as a discretionary share sale. After these transactions, Wijkstrom directly held 333,469 shares of Vanda common stock. The trades were completed in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos reported an open-market sale of 156,235 shares of common stock at a weighted average price of $8.1734 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under RSU agreements.
After this transaction, the reporting person directly owned 2,704,496 shares of Vanda Pharmaceuticals common stock.
Vanda Pharmaceuticals Inc. senior vice president of business development Gunther Birznieks reported an open-market sale of 42,431 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations tied to the settlement of vested RSUs. After these transactions, he directly holds 494,197 shares. The sales occurred in multiple trades priced between $8.085 and $8.81 per share.
Vanda Pharmaceuticals director Honore Tage sold 30,000 shares of common stock in an open-market transaction at a price of $8.03 per share. After this sale, Tage directly owns 93,469 shares of Vanda Pharmaceuticals common stock.